SMT201500281B - Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari - Google Patents
Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolariInfo
- Publication number
- SMT201500281B SMT201500281B SM201500281T SM201500281T SMT201500281B SM T201500281 B SMT201500281 B SM T201500281B SM 201500281 T SM201500281 T SM 201500281T SM 201500281 T SM201500281 T SM 201500281T SM T201500281 B SMT201500281 B SM T201500281B
- Authority
- SM
- San Marino
- Prior art keywords
- rostafuroxine
- cardiovascular conditions
- pharmacogenomic treatment
- pharmacogenomic
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25302009P | 2009-10-19 | 2009-10-19 | |
| EP09177111 | 2009-11-25 | ||
| PCT/EP2010/065589 WO2011048033A2 (en) | 2009-10-19 | 2010-10-18 | Methods and systems for pharmacogenomic treatment of cardiovascular conditions |
| EP10807525.0A EP2490694B1 (en) | 2009-10-19 | 2010-10-18 | Rostafuroxine for pharmacogenomic treatment of cardiovascular conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201500281B true SMT201500281B (it) | 2016-01-08 |
Family
ID=41727473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201500281T SMT201500281B (it) | 2009-10-19 | 2015-11-12 | Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9408854B2 (it) |
| EP (1) | EP2490694B1 (it) |
| JP (3) | JP2013508329A (it) |
| KR (3) | KR102053470B1 (it) |
| CN (1) | CN102695512B (it) |
| AU (1) | AU2010309921B2 (it) |
| BR (1) | BR112012009144B8 (it) |
| CA (1) | CA2777310C (it) |
| DK (1) | DK2490694T3 (it) |
| EA (1) | EA201270574A1 (it) |
| ES (1) | ES2551877T3 (it) |
| HR (1) | HRP20151185T1 (it) |
| HU (1) | HUE028075T2 (it) |
| IL (1) | IL219173A (it) |
| ME (1) | ME02347B (it) |
| MX (1) | MX2012004559A (it) |
| PL (1) | PL2490694T3 (it) |
| PT (1) | PT2490694E (it) |
| RS (1) | RS54416B1 (it) |
| SG (1) | SG10201406457VA (it) |
| SI (1) | SI2490694T1 (it) |
| SM (1) | SMT201500281B (it) |
| WO (1) | WO2011048033A2 (it) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012066141A1 (en) * | 2010-11-19 | 2012-05-24 | Fondazione Centro San Raffaele Del Monte Tabor | Markers for acute kidney injury and uses thereof |
| CN102940640A (zh) * | 2012-12-06 | 2013-02-27 | 中国生命药物治疗有限公司 | 罗他夫辛在制备治疗基因缺陷型原发性高血压的药物中的用途 |
| EP2937421B1 (en) * | 2014-04-03 | 2018-10-24 | Samsung Electronics Co., Ltd | Biomarker for predicting effect of an anti-C-met antibody |
| KR102338678B1 (ko) * | 2014-04-03 | 2021-12-13 | 삼성전자주식회사 | 항 c-Met 항체 효과 예측을 위한 바이오마커 |
| US11761043B2 (en) | 2014-05-29 | 2023-09-19 | Geneticure Inc. | Machine assay and analysis for selecting antihypertensive drugs |
| US10590485B2 (en) | 2014-05-29 | 2020-03-17 | Geneticure Llc | Therapeutic regimen for hypertension |
| EP2977758A1 (en) * | 2014-07-24 | 2016-01-27 | Université De Nice Sophia Antipolis | Methods and kits for monitoring membranous nephropathy |
| CN107447014A (zh) * | 2015-01-21 | 2017-12-08 | 田小利 | Thsd7a基因序列及表达改变检测及其在冠心病预测中的应用 |
| JP2019515369A (ja) * | 2016-03-29 | 2019-06-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 遺伝的バリアント−表現型解析システムおよび使用方法 |
| CN108728522A (zh) * | 2018-06-11 | 2018-11-02 | 苏州艾达康医疗科技有限公司 | 药物基因组检测方法 |
| US11337988B2 (en) | 2018-09-27 | 2022-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of ouabain antagonists to inhibit viral infection |
| US11600375B2 (en) | 2021-07-30 | 2023-03-07 | Reviv Global Ltd | Genetically personalized food recommendation systems and methods |
| US11894121B2 (en) | 2021-08-06 | 2024-02-06 | Reviv Global Ltd | Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods |
| US12417834B2 (en) | 2021-07-30 | 2025-09-16 | Reviv Global Ltd | Genetically personalized intravenous and intramuscular nutrition therapy design systems and methods |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9001181D0 (en) | 1990-01-18 | 1990-03-21 | Imp Cancer Res Tech | Genetic assay |
| DE4227616C2 (de) | 1992-08-20 | 1995-04-13 | Sigma Tau Ind Farmaceuti | 17-(3-Furyl)-und 17-(4-Pyridazinyl)-5beta, 14beta-androstanderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammemsetzungen |
| US5632276A (en) | 1995-01-27 | 1997-05-27 | Eidelberg; David | Markers for use in screening patients for nervous system dysfunction and a method and apparatus for using same |
| SE9501782D0 (sv) | 1995-05-12 | 1995-05-12 | Landstinget I Oestergoetland | Method of predicting the therapeutic response of a drug against a malignant tumour |
| US6566332B2 (en) * | 2000-01-14 | 2003-05-20 | Genset S.A. | OBG3 globular head and uses thereof for decreasing body mass |
| WO2001053537A2 (en) * | 2000-01-24 | 2001-07-26 | Dzgenes, Llc | Nitric oxide synthase gene diagnostic polymorphisms |
| AU2001257421A1 (en) | 2000-04-28 | 2001-11-12 | Sangamo Biosciences, Inc. | Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions |
| US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
| US6867189B2 (en) * | 2001-07-26 | 2005-03-15 | Genset S.A. | Use of adipsin/complement factor D in the treatment of metabolic related disorders |
| US20040166491A1 (en) * | 2001-08-09 | 2004-08-26 | Henderson Lee A | Vhl promoter diagnostic polymorphism |
| WO2003018745A2 (en) * | 2001-08-21 | 2003-03-06 | Glaxo Group Limited | Method of screening for drug hypersensitivity reaction |
| JP2005514010A (ja) * | 2001-10-12 | 2005-05-19 | セローノ ジェネティクス インスティテュート ソシエテ アノニム | Ｎｇｚｉｐａ、ｎｇｚｉｐｄ、ｐｇｚｉｐａおよびｐｇｚｉｐｄポリヌクレオチドおよびポリペプチド、ならびにその使用 |
| WO2003095485A2 (en) * | 2002-05-10 | 2003-11-20 | Serono Genetics Institute S.A. | Krib polynucleotides and polypeptides and uses thereof in the treatment of metabolic disorders |
| JP2009520460A (ja) | 2003-03-10 | 2009-05-28 | アプレラ コーポレイション | 心筋梗塞に関連する遺伝的多型、その検出方法および使用 |
| DE602005021525D1 (de) | 2004-09-14 | 2010-07-08 | Univ Colorado | R behandlung mit bucindolol |
| PL1951738T3 (pl) * | 2005-11-25 | 2012-06-29 | Cvie Therapeutics Ltd | Nowe formy krystaliczne rostafuroksyny |
| WO2009008412A1 (ja) * | 2007-07-06 | 2009-01-15 | National Institute Of Radiological Sciences | 放射線治療後における泌尿器の晩期有害反応の発症予測用ｄｎａチップ、及びこれを用いた放射線治療後における泌尿器の晩期有害反応の発症予測方法 |
| JP5476536B2 (ja) * | 2007-10-03 | 2014-04-23 | 独立行政法人放射線医学総合研究所 | 乳癌の放射線治療による晩期副作用の発症を予測する方法 |
| US20090221620A1 (en) * | 2008-02-20 | 2009-09-03 | Celera Corporation | Gentic polymorphisms associated with stroke, methods of detection and uses thereof |
| JP2010106007A (ja) | 2008-08-14 | 2010-05-13 | Sony Corp | 薬剤徐放剤、吸着剤、機能性食品、マスク及び吸着シート |
| UA103664C2 (ru) * | 2009-03-23 | 2013-11-11 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | 5-β-ПРОИЗВОДНЫЕ 14-β-АНДРОСТАНА ДЛЯ ЛЕЧЕНИЯ ПРОТЕИНУРИИ, ГЛОМЕРУЛОСКЛЕРОЗА И ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ |
-
2010
- 2010-10-18 EP EP10807525.0A patent/EP2490694B1/en active Active
- 2010-10-18 CN CN201080047339.7A patent/CN102695512B/zh not_active Expired - Fee Related
- 2010-10-18 CA CA2777310A patent/CA2777310C/en active Active
- 2010-10-18 PL PL10807525T patent/PL2490694T3/pl unknown
- 2010-10-18 KR KR1020147008190A patent/KR102053470B1/ko not_active Expired - Fee Related
- 2010-10-18 HU HUE10807525A patent/HUE028075T2/en unknown
- 2010-10-18 BR BR112012009144A patent/BR112012009144B8/pt not_active IP Right Cessation
- 2010-10-18 SI SI201031049T patent/SI2490694T1/sl unknown
- 2010-10-18 EA EA201270574A patent/EA201270574A1/ru unknown
- 2010-10-18 US US13/502,518 patent/US9408854B2/en not_active Expired - Fee Related
- 2010-10-18 ES ES10807525.0T patent/ES2551877T3/es active Active
- 2010-10-18 KR KR1020127012864A patent/KR20120093297A/ko not_active Ceased
- 2010-10-18 RS RS20150749A patent/RS54416B1/sr unknown
- 2010-10-18 PT PT108075250T patent/PT2490694E/pt unknown
- 2010-10-18 KR KR1020177030589A patent/KR20170121325A/ko not_active Ceased
- 2010-10-18 WO PCT/EP2010/065589 patent/WO2011048033A2/en not_active Ceased
- 2010-10-18 HR HRP20151185TT patent/HRP20151185T1/hr unknown
- 2010-10-18 SG SG10201406457VA patent/SG10201406457VA/en unknown
- 2010-10-18 AU AU2010309921A patent/AU2010309921B2/en not_active Ceased
- 2010-10-18 MX MX2012004559A patent/MX2012004559A/es active IP Right Grant
- 2010-10-18 JP JP2012534642A patent/JP2013508329A/ja active Pending
- 2010-10-18 ME MEP-2015-174A patent/ME02347B/me unknown
- 2010-10-18 DK DK10807525.0T patent/DK2490694T3/en active
-
2012
- 2012-04-15 IL IL219173A patent/IL219173A/en active IP Right Grant
-
2013
- 2013-08-13 JP JP2013168314A patent/JP6130268B2/ja not_active Expired - Fee Related
-
2015
- 2015-02-25 JP JP2015035883A patent/JP2015128435A/ja active Pending
- 2015-11-12 SM SM201500281T patent/SMT201500281B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201500281B (it) | Rostafuroxina per il trattamento farmacogenomico di condizioni cardiovascolari | |
| SMT201600254B (it) | Procedimento per la preparazione di idromagnesite | |
| DK3192520T3 (da) | Terapeutiske midler til reducering af niveauerne af parathyreoideahormon | |
| ME02117B (me) | 2-aminobenzimidazol-5-karboksamidi kao anti-inflamatorni agensi | |
| SMT202000086T1 (it) | Bardoxolone metile per il trattamento dell'obesità | |
| IT1393061B1 (it) | Procedimento integrato per la produzione di bio-olio da microrganismi | |
| GB0915515D0 (en) | Treatment of vasculoproliferative conditions | |
| SG2014014724A (en) | METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS | |
| IL212119A0 (en) | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | |
| GB0904285D0 (en) | Compounds for the treatment of metabolic disorders | |
| SMT201400165B (it) | Composizioni e metodi per il trattamento di sclerosi multipla | |
| GB0904287D0 (en) | Compounds for the treatment of metabolic disorders | |
| ZA201107445B (en) | Compound for the treatment of metabolic disorders | |
| IL215377A0 (en) | Method of genotyping | |
| IT1403587B1 (it) | Composizione per il trattamento di disordini metabolici | |
| IT1398729B1 (it) | Processo per la preparazione di testosterone | |
| SMT201600479T1 (it) | Nuove soluzioni terapeutiche per il trattamento di condizioni neuroinfiammatorie | |
| PL2493305T3 (pl) | Związki 2-aminoindolowe i sposoby leczenia malarii | |
| GB0903740D0 (en) | Mrthod for reducing the viscosity of biosolids | |
| IT1394292B1 (it) | Procedimento per la sintesi di pregabalina | |
| IT1399040B1 (it) | Procedimento per il rinforzo di elementi strutturali | |
| TWM370404U (en) | Structure of compound massage set | |
| IT1398273B1 (it) | Procedimento per la preparazione di 14-bromo daunomicina | |
| IT1397499B1 (it) | Processo per la preparazione di ciclesonide | |
| GB0804468D0 (en) | Treatment of influenza |